Benjamin Berger

8PUBLICATIONS
16CO-AUTHORS
Metabolic medicineCheminformatics and quantitative structure-activity relationshipsPharmacogenomicsCharacterisation of biological macromoleculesToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 20, 2026
Population Pharmacokinetic Modeling for the Iminosugar Lucerastat Supports Dose Adaptation in Patients With Fabry Disease and Moderate to Severe Renal Function Impairment.

|May 27, 2024
Value of Assessing 1-Hydroxymidazolam in Drug-Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A.

Massimo Magliocca, Benjamin Berger, Vincent Lemoine

|Oct 06, 2023
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.

Benjamin Berger, Priska Kaufmann, Matthias Berse

|Apr 12, 2023
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivo.

Marion Anliker-Ort, Jasper Dingemanse, Stephane Delahaye

|Jun 14, 2021
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment.

Benjamin Berger, Clemens Muehlan, Gernot Klein

|May 18, 2021
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.

Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini

Pageof 2

Frequent Collaborators

8 joint publications

Jasper Dingemanse

4 joint publications

Priska Kaufmann

3 joint publications

Clemens Muehlan

1 joint publications

Sander Brooks